Has Ross Vogelgesang, MD received payments from drug or device companies?

Yes. Drug and device makers reported $20,648 in general payments to Ross Vogelgesang, MD across 376 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ross Vogelgesang, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ross Vogelgesang, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ross Vogelgesang, MD

Pain Medicine · Olympia, WANPI 1518919505

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (42.0%), travel and lodging and other — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Nevro Corp. at 48.7% of the total. Reporting peaked in 2020 at $7,353 and has fallen 92.6% since, to $548 in 2025. Among pain medicine clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,648in general payments, 2019–2025

Across 376 payments — averaging $54.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Nevro Corp.$10K
Medtronic$5K
Genesys Orthopedics Systems, L.L.C.$1K
Zyla Life Sciences, Inc.$797
Collegium Pharmaceutical, Inc.$632
AbbVie$344
plus $3K from 33 others

What the payments were for

Consulting fees$1,5758%
Travel & lodging$4,85123%
Food & beverage$8,67542%
Education$1,0105%
Gifts$110%
Other$4,52622%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Nevro Corp.	99	$10,054
Medtronic(2 entities)	15	$4,994
Genesys Orthopedics Systems, L.L.C.	4	$1,036
Zyla Life Sciences, Inc.	69	$797
Collegium Pharmaceutical, Inc.	41	$632
AbbVie(2 entities)	19	$344
Biodelivery Sciences International, Inc.	13	$304
Daiichi Sankyo Inc.	18	$246
Boston Scientific	3	$174
Vertos Medical, Inc.	3	$174
Scilex Pharmaceuticals Inc.	10	$174
Si-bone, Inc.	4	$159
Globus Medical	1	$144
Pfizer	7	$133
Amgen(2 entities)	7	$128
Virtus Pharmaceuticals LLC	5	$101
Abbott	5	$99
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	6	$99
Nalu Medical, Inc.	3	$90
Assertio Therapeutics, Inc.	5	$86
Kaleo, Inc.	5	$75
Sentynl Therapeutics, Inc.	5	$69
SPR Therapeutics, Inc	3	$63
MDD US Operations, LLC	3	$62
Vertex	2	$48
Arbor Pharmaceuticals, Inc.	3	$47
Biohaven Pharmaceuticals, Inc.	3	$46
Teva Pharmaceuticals USA, Inc.	2	$33
Biohaven Pharmaceutical Holding Company Ltd.	2	$32
Kowa Pharmaceuticals America, Inc.	2	$31
Fidia Pharma USA Inc.	1	$28
Relievant Medsystems, Inc.	1	$23
Redhill Biopharma Inc.	1	$22
Merz Pharmaceuticals, LLC	1	$19
Convatec Inc.	1	$19
Vertical Pharmaceuticals, LLC	1	$17
Evofem Biosciences, Inc.	1	$16
Ultragenyx Pharmaceutical Inc.	1	$16
Lilly USA, LLC	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Senza Spinal Cord Stimulation System$5,198
Senza$2,077
SI Joint$1,013
Omnia$245
INTELLIS ADAPTIVESTIM$170
INTELLIS$131
GENERAL PAIN MANAGEMENT$121
BELBUCA$121

How this compares

$20,648 in reported general payments places this provider in the 90th percentile of 124 pain medicine providers in Washington.

See all pain medicine providers in Washington →

Medicare billing

Part B allowed, 2024

$144,403

Medicare patients

392

Services billed

2,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl	52	$14,446
Pregabalin	167	$7,425
Duloxetine Hcl	105	$968
Gabapentin	56	$812
Baclofen	45	$753
Tramadol Hcl	96	$649
Cephalexin	46	$551
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	15	$347
Tizanidine Hcl	25	$301
Oxycodone Hcl	16	$116
Hydromorphone Hcl	17	$109
Meloxicam	21	$100
Methocarbamol	16	$87

Paid to pharmacies, not to this prescriber.

Other pain medicine in Olympia

Peter ParkOlympia$19K
Douglas TaylorOlympia$11K
Thomas YangOlympia$5K
Jennifer LeeKirkland$318K
Steven StanosSeattle$206K
Corrie AndersonSeattle$102K
Gregory TermanSeattle$95K
Caroline HarstroemEverett$74K
Sloane YuVancouver$42K
Praveen MambalamEdmonds$32K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →